
The European Commission has signed a joint procurement contract for an antiviral treatment for patients with COVID-19 with Gilead Sciences Inc, it said on Tuesday.
This is the second contract for the drug, branded as Veklury, which is approved in Europe to treat COVID patients who are at high risk of experiencing a severe case of the disease, as well as patients who have pneumonia and require supplemental oxygen.